HHS warns of major furloughs as shutdown threat looms

30 September 2025

The US Department of Health and Human Services (HHS) has warned that more than 32,000 of its staff could be furloughed if Congress fails to avert a federal government shutdown this week, raising the risk of disruption across public health and medical research.

The contingency plan, covering 41% of the 79,717-strong workforce, would spare high-profile services such as Medicare, Medicaid, Affordable Care Act programs, and Food and Drug Administration drug approvals. But the Centers for Disease Control and Prevention faces losing nearly two-thirds of its personnel, stalling communication with state health departments on crises such as opioid overdoses, HIV, and diabetes prevention. The National Institutes of Health would be forced to furlough three-quarters of its staff, halting grant reviews, advisory council meetings, and most laboratory work.

HHS said the Clinical Center at NIH could only admit new patients where medically necessary. Contractor oversight, public health messaging, and guidance for local officials would also be sharply curtailed. By contrast, the FDA expects to retain 86% of its employees, while the Centers for Medicare and Medicaid Services would keep just over half its workforce.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight



More Features in Pharmaceutical